Peptides

Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity

Retrieved on: 
Tuesday, August 3, 2021
Medicine, Medical specialties, Clinical medicine, Nutrition, Bariatrics, Anorectics, Peptides, Setmelanotide, Obesity, Disease, Rare disease, Genetic disorder

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced a significant expansion of its clinical development program for setmelanotide with five new planned Phase 2 and 3 clinical trials. Rhythm will review these updates on its second quarter 2021 financial results and business update conference call today at 8 a.m. ET.

Key Points: 
  • We are excited to announce the significant expansion of our development program for setmelanotide.
  • These rare genetic diseases of obesity are serious, life-threatening diseases that affect children with early-onset, severe obesity.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity.
  • Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity.

Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists

Retrieved on: 
Wednesday, July 28, 2021
GnRH antagonists, Ureas, Peptides

The amended agreement provides for the concurrent development of multiple oral IL-23 receptor antagonists against a broad range of indications.

Key Points: 
  • The amended agreement provides for the concurrent development of multiple oral IL-23 receptor antagonists against a broad range of indications.
  • Protagonist remains eligible to potentially receive approximately $900 million in future development and sales milestones, in addition to the $80 million in payments already received under the original agreement.
  • Janssen will have the right to continue research on IL-23 receptor antagonists developed during the collaboration for three years from the closing of the Restated Agreement.
  • The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of oral peptide IL-23 receptor antagonists.

EQS-News: Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita

Retrieved on: 
Wednesday, July 28, 2021
Medical specialties, Aviptadil, Peptides, Branches of biology, Respiratory distress syndrome, Volume-weighted average price, Acute respiratory distress syndrome, Clinical medicine

Under the terms of the agreement, Relief paid AdVita shareholders a total of 135,741,063 Relief common shares, representing EUR 25 million in value based on a 60-day Volume-Weighted Average Price (VWAP) of Relief's common stock, to acquire all outstanding shares of AdVita.

Key Points: 
  • Under the terms of the agreement, Relief paid AdVita shareholders a total of 135,741,063 Relief common shares, representing EUR 25 million in value based on a 60-day Volume-Weighted Average Price (VWAP) of Relief's common stock, to acquire all outstanding shares of AdVita.
  • In addition, Relief will pay milestone payments of up to EUR 20 million in cash, contingent to achievement of certain regulatory milestones related to AdVita's development programs.
  • Jack Weinstein, Chief Financial Officer and Treasurer of Relief, said: "We are pleased to close this acquisition, which brings to Relief additional intellectual property concerning inhaled formulations of aviptadil.
  • In April, Relief and AdVita initiated an investigator-sponsored phase 2 trial with inhaled aviptadil for the prevention of COVID-19-related acute respiratory distress syndrome.

EQS-News: Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia

Retrieved on: 
Wednesday, July 28, 2021
Aviptadil, Peptides, Relief Therapeutics

Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia

Key Points: 
  • Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia
    Relief Reports that its U.S.
  • Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale.
  • As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001.
  • In addition, Relief's recently completed acquisition of APR Applied Pharma Research brings a diverse pipeline of marketed and development-stage programs.

Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

Retrieved on: 
Tuesday, July 27, 2021
Medicine, Clinical medicine, Medical specialties, Anorectics, Breakthrough therapy, Peptides, Setmelanotide, Obesity, Rare disease, Disease

ET on Tuesday, August 3, 2021 to report its second quarter 2021 financial results and provide a corporate update.

Key Points: 
  • ET on Tuesday, August 3, 2021 to report its second quarter 2021 financial results and provide a corporate update.
  • A webcast of the call will also be available under Events & Presentations in the Investor Relations section of the Rhythm website at ir.rhythmtx.com.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity.
  • Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity.

 Women in India are the first in the world to receive new heat-stable carbetocin formulation to prevent excessive bleeding after childbirth

Retrieved on: 
Monday, July 26, 2021
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Women's health, Human reproduction, Medical specialties, Motherhood, Transfusion medicine, Midwifery, Childbirth, Carbetocin, Peptides, Postpartum bleeding, Bleeding, Caesarean section

Heat-stable carbetocin is now available for use in healthcare facilities across India, in the prevention of excessive bleeding following vaginal and caesarean section births.

Key Points: 
  • Heat-stable carbetocin is now available for use in healthcare facilities across India, in the prevention of excessive bleeding following vaginal and caesarean section births.
  • Until now, the first-choice drug for preventing excessive bleeding after birth required storage and transportation at 28C, typically in a refrigerator to maintain its effectiveness.
  • Carbetocin Ferring is a heat-stable formulation with predictable quality offering an additional option for healthcare professionals in preventing excessive bleeding after childbirth.
  • Ferring statement on subsidised pricing of heat-stable carbetocin for the prevention of postpartum haemorrhage in low- and lower-middle income countries.

EQS-News: Relief Reports that its U.S. Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil

Retrieved on: 
Friday, July 23, 2021
Peptides, Aviptadil, Acer Inc., Consumer electronics, Companies, Electronics industry

Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil

Key Points: 
  • Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil
    Relief Reports that its U.S.
  • NRx also reported in its press release that it had achieved a 30-to-50-fold increase in its manufactured lot size of aviptadil.
  • Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, said: "We are pleased that our collaboration partner has reported that it has developed a formulation of aviptadil that it reports is suitable for commercial distribution.
  • As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001.

NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval

Retrieved on: 
Thursday, July 22, 2021
Natural sciences, Physical sciences, Chemistry, Peptides, Aviptadil, Nuclear reactors, Atomic Energy of Canada Limited, Pharmacology, Nrx, Pharmaceutical industry, Nrx, Assay

These two developments position NRx to potentially deliver millions of doses of ZYESAMI as potential regulatory approvals are obtained in various regions worldwide.

Key Points: 
  • These two developments position NRx to potentially deliver millions of doses of ZYESAMI as potential regulatory approvals are obtained in various regions worldwide.
  • "We have now turned the corner and can produce both the aviptadil peptide and finished medicine in million dose quantities.
  • We have also developed and validated the first modern chromatography assays required to ensure the purity and stability of the drug product.
  • NRx Pharmaceuticals ( www.nrxpharma.com ) (NRx) draws upon more than 300 years of collective, scientific and drug-development experience to bring improved health to patients.

EQS-News: Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19

Retrieved on: 
Tuesday, July 20, 2021
Medical specialties, Immunology, Health, Aviptadil, Peptides, Clinical medicine, Cytokine storm, Cytokine, COVID-19, Relief Therapeutics

Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19

Key Points: 
  • Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19
    Relief Reports that its U.S.
  • They reported that the cytokine data were collected as part of the U.S. phase 2b/3 trial of aviptadil compared to placebo in critically ill patients with COVID-19 respiratory failure.
  • Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale.
  • In addition, Relief's recently completed acquisition of APR Applied Pharma Research brings a diverse pipeline of marketed and development-stage programs.

ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity

Retrieved on: 
Monday, July 19, 2021
Peptides, Infectious diseases, Health care, Bacterial diseases, Antibiotics, Healthcare-associated infections, Cyclic peptides, Depsipeptides, Daptomycin, Methicillin-resistant Staphylococcus aureus, Vancomycin

The analysis of bone samples demonstrated that CF-296 has potent anti-staphylococcal activity and, when used with daptomycin, is active and well tolerated in MRSA acute osteomyelitis.

Key Points: 
  • The analysis of bone samples demonstrated that CF-296 has potent anti-staphylococcal activity and, when used with daptomycin, is active and well tolerated in MRSA acute osteomyelitis.
  • Of note, the addition of CF-296 to both daptomycin or vancomycin resulted in significantly enhanced antibacterial activity in the model, relative to the activity of these standard-of-care antibiotics alone.
  • ContraFect continues to evaluate CF-296 in further preclinical studies and the potential for future clinical development.
  • CF-296 was developed by ContraFect and the Company is actively pursuing global rights to this investigational development candidate.